Clover's COVID-19 Vaccine Confirms Commercial Priorities
Clover Biopharmaceuticals, Ltd. today provided updates on the commercial launch for SCB-2019 (CpG 1018/Alum) in China in multiple provinces and municipalities, expected to begin in Q1 2023.
Given the scale and impact of the ongoing COVID-19 outbreaks across China, Clover now anticipates a significant and sustained long-term annual booster market opportunity in China for Clover’s premium and broadly protective COVID-19 vaccine.
“Clover transformed into a commercial-stage, vaccines-focused biotech company with proven R&D capabilities in 2022. In 2023, we are focused on launching our vaccine in multiple countries and working with health authorities in China and globally to increase booster coverage for vulnerable populations,” said Joshua Liang, Chief Executive Officer and Executive Director of Clover, in a press release on January 15, 2023.
“We also plan to expand our mid- to late-stage vaccine pipeline for near-term value creation by leveraging our established vaccine development and proven cross-border collaboration capabilities.”
Concurrent with its commercial launch in China, Clover plans to conduct real-world effectiveness studies, with data potentially available in H2 2023.
These studies could provide valuable insight into preventing severe disease, hospitalization, and death due to COVID-19 caused by newly circulating Omicron variants in at-risk populations.
This data can strengthen SCB-2019’s commercial value and competitive positioning.
Dr. Nicholas Jackson, President of Global Research and Development of Clover. “We are excited to share our development plans to build a leading respiratory vaccine franchise and establish a presence in the pediatric vaccine market in China and the Asia Pacific, further strengthening Clover’s competitive advantages and contribution to global health.”